We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
CanSinoBIO’s inhaled COVID-19 vaccine candidate was found to trigger immune responses with no serious side effects reported, according to an early-stage clinical study.